Structure-activity relationships and inhibitory effects of various purine derivatives on the in vitro growth of Plasmodium falciparum.
The development of novel chemotherapeutic agents has become an urgent task due to the development and rapid spread of drug resistance in Plasmodium falciparum, the protozoan parasite responsible for cerebral malaria. Cyclin-dependent kinases (CDKs) are essential for the regulation of the eukaryotic cell cycle, and several enzymes of this family have been identified in P. falciparum. In recent years, a number of purine-derived kinase inhibitors have been synthesised, some of which display selective activity against CDKs. This report describes a study in which various purine derivatives were screened for in vitro antimalarial activity. The erythrocytic asexual stages of the chloroquine-resistant P. falciparum strain (FCR-3) were cultivated in vitro in the presence of the various purines, and their effect on parasite proliferation was determined by the [3H]hypoxanthine incorporation assay. Our results show considerable variation in the sensitivity of P. falciparum to the different purines, as well as a general independence from their effect on purified starfish CDK1/cyclin B activity, which has been the standard assay used to identify CDK-specific inhibitors. Two subfamilies of purines with moderate to poor activity against CDK1/cyclin B activity showed submicromolar activity against P. falciparum. Structure-activity analysis indicates that certain structural features are associated with increased activity against P. falciparum. These features can be exploited to synthesise compounds with higher activity and specificity towards P. falciparum.
Harmse
L
L
Department of Experimental and Clinical Pharmacology, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, 2193, Parktown, South Africa. leoni@hixnet.co.za
van Zyl
R
R
Gray
N
N
Schultz
P
P
Leclerc
S
S
Meijer
L
L
Doerig
C
C
Havlik
I
I
D000225:Adenine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D000962:Antimalarials / Q000737:chemistry / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D007541:Isopentenyladenosine; D007701:Kinetin; D021261:Parasitic Sensitivity Tests; D010770:Phosphotransferases / Q000378:metabolism; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000254:growth & development; D011687:Purines / Q000737:chemistry / Q000494:pharmacology*; D000077546:Roscovitine; D013329:Structure-Activity Relationship
D000962:Antimalarials; D011687:Purines; C113584:purvalanol B; D000077546:Roscovitine; C001478:N(6)-(delta(2)-isopentenyl)adenine; C090046:olomoucine; D007541:Isopentenyladenosine; D010770:Phosphotransferases; D000225:Adenine; D007701:Kinetin